Weeteck Yeo

Weeteck is SVP of Business Operations and Chief of Staff at Draig Therapeutics. He oversees corporate development, finance, investor relations, operations, and commercial strategy/preparation at Draig. He has more than 20 years of experience in business development, external innovation, transactions, investment and finance, corporate strategy, and business operations. He started his career in equity research at Deutsche Bank and Jefferies before joining Teva Pharmaceuticals Industries Ltd and Ipsen. Prior to joining Draig, Weeteck was SVP, Strategic Operations and a founding team member at Vigil Neuroscience, which was acquired by Sanofi in August 2025. 

Weeteck has a PhD in Genetics and Developmental Biology from Columbia University, and graduated with a first-class honours degree in Biochemistry and Molecular Biology from the University of Manchester, Institute of Science and Technology.